

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models

Elisa Callegari, Paola Guerriero, Cristian Bassi, Lucilla D'Abundo, Antonio Frassoldati, Edi Simoni, Laura Astolfi, Enrico Maria Silini, Silvia Sabbioni, and Massimo Negrini

Correspondence: silvia.sabbioni@unife.it, massimo.negrini@unife.it
<https://doi.org/10.1016/j.omtn.2022.10.017>

(Molecular Therapy: Nucleic Acids 29, 538–549; September 2022)

In the originally published version of this article, the Y axis scale in Figure 2F was incorrect. The major tick intervals were wrongly indicated as 0, –10, and –15. The new corrected figure indicates the intervals as 0, –5, and –10. This change is reflected online, and authors apologize for this error and any confusion it may have caused.






Figure 2. miR-199a-3p increased palbociclib efficacy on human HCC cells *in vitro* and *in vivo* (corrected)




Figure 2. miR-199a-3p increased palbociclib efficacy on human HCC cells *in vitro* and *in vivo* (original)